ProCE Banner Activity

TRIDENT-1 Update: Phase I/II Study of Repotrectinib in Patients With ROS1 Fusion–Positive Advanced NSCLC

Conference Coverage

With a median follow-up of more than 20 months, the next-generation ROS1/TRK TKI repotrectinib demonstrated durable clinical activity in both ROS1 TKI–naive and previously exposed patients with ROS1 fusion–positive advanced NSCLC, including evidence of intracranial efficacy.

Released: September 15, 2023


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc, Gilead Sciences Inc., and Regeneron Pharmaceuticals, Inc.


Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

Regeneron Pharmaceuticals, Inc